Latvian Early Atherosclerosis Registry

Summary

Atherosclerosis and its complications are a global problem. There are several widely known and proven risk factors that promotes atherogenesis in the majority of patients. However, significant proportion of apparently healthy and young patients with cardiovascular disease but yet without recognized atherogenesis promoting risk factors can be observed in clinical practice. It highlights the need of new risk markers for early atherosclerosis diagnostics to prevent serious cardiovascular complications in these patients and in population in general. The interest in the negative impact of genetic variance, gene regulation on atherogenesis is growing. Therefore the purpose of this study is to analyze the impact of genetic variance and microRNA expression on early atherosclerosis development in the population of young, apparently healthy patients with coronary atherosclerosis. The primary hypothesis is that the group of patients with premature atherosclerosis have common genetic variations promoting early atherosclerosis development. The secondary hypothesis is that specific circulating microRNA expression (miR-126, miR-145 and miR-155) correlate with plaque lipid core by near infrared spectroscopy (NIRS) analysis.

Eligibility

Inclusion criteria:

* Signed informed consent
* Early atherosclerosis defined as coronary atherosclerosis in men aged \<55 years and women \<65 years
* Coronary artery atherosclerosis with angiographically proven coronary vessel luminal stenosis ≥ 50% and ischaemia
* Coronary artery atherosclerosis with planned revascularization
* History of coronary artery revascularization (PTCA or coronary artery bypass surgery)
* Coronary vessel suitable for NIRS pullback

Exclusion criteria:

* Diabetes
* Total cholesterol ≥7 mmol/l and/or LDL ≥ 5 mmol/l
* family hypercholesterolemia
* positive family history of early cardiovascular disease (myocardial infarction, sudden cardiac death or cardiovascular disease of first degree relatives at young age - men \<55 years, women \<65 years)
* malignant or resistant hypertension ≥ 10 years
* body mass index ≥40 kg/m 2 )
* 20 or more pack years of smoking

Conditions3

Browse More Trials